“Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15)

Yu-Chun Lie

“Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15)

Electrical and Computer Engineering

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Default journal
State	Published - 2019

Fingerprint

Dive into the research topics of '“Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15)'. Together they form a unique fingerprint.

Cite this

Lie, Y-C. (2019). “Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15). Default journal.

Lie, Yu-Chun. / “Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15). In: Default journal. 2019.

@article{517b447da78a4829947fac78078ba657,

title = "“Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15)",

author = "Yu-Chun Lie",

year = "2019",

language = "English",

journal = "Default journal",

publisher = "Current Opinion in Endocrinology Diabetes and Obesity",

}

Lie, Y-C 2019, '“Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15)', Default journal.

“Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15). / Lie, Yu-Chun.
In: Default journal, 2019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - “Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15)

AU - Lie, Yu-Chun

PY - 2019

Y1 - 2019

M3 - Article

JO - Default journal

JF - Default journal

ER -

Lie Y-C. “Latest Treatment Options to Overcome Acquired Resistance to Osimertinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior EGFR-TKI Therapies”, Tam Q. Nguyen, Paul E. Lie, Donald Y.C. Lie and Lukman Tijani, International Journal of Advances in Science, Engineering and Technology (IJASEAT), Volume 7, Issue-3, pp. 77-82, 2019 http://www.iraj.in/journal/journal_file/journal_pdf/6-580-157129166377-82.pdf (JIF: 3.15). Default journal. 2019.